Plunkett Research Online: Autolus Therapeutics PLC

AUTOLUS THERAPEUTICS PLC (AUTL:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8......



Autolus Therapeutics PLC
Ticker: AUTL
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 44 2038296230
Fax:
Address: 191 Wood Lane
The MediaWorks
London, W12 7FP United Kingdom

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biotechnology

Ranks not available
Contacts Description
Christian Itin CEO/Director
Andrew Oakley CFO/Senior VP
See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2021 2020 2019 2018 2018 2017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Name Title Salary (GBP) Bonus (GBP)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: